EGFR外显子20插入突变肺癌中EGFR酪氨酸激酶抑制剂的耐药机制
本研究从接受莫博赛替尼、波齐替尼和埃万妥单抗治疗的EGFR外显子20插入突变非小细胞肺癌患者中采集治疗前及耐药后的组织和cfDNA样本,通过全基因组和靶向测序分析遗传改变,并构建体外耐药细胞系验证。结果发现莫博赛替尼耐药时出现EGFR扩增(n=6,包括2例广泛拷贝数增加)和EGFR二次突变(n=3),其中1例同时具有EGFR二次突变和高水平EGFR局灶扩增。体外模型证实获得性EGFR依赖性改变介导莫博赛替尼耐药。6例接受序贯埃万妥单抗后EGFR酪氨酸激酶抑制剂治疗的患者中,2例有MET扩增并显示部分缓解。结论揭示EGFR依赖性和非依赖性莫博赛替尼耐药机制。
要点
- 莫博赛替尼耐药时可见EGFR扩增(n=6,含2例广泛拷贝数增加)和EGFR二次突变(n=3)。
- 1例患者同时具有EGFR二次突变和高水平EGFR局灶扩增。
- 6例序贯埃万妥单抗后EGFR酪氨酸激酶抑制剂治疗患者中,2例有MET扩增并显示部分缓解。
核心结论
- 本研究揭示了晚期EGFR外显子20插入突变非小细胞肺癌患者中莫博赛替尼耐药的EGFR依赖性和非依赖性机制。
研究设计与样本
- 从接受莫博赛替尼、波齐替尼和埃万妥单抗治疗的EGFR外显子20插入突变非小细胞肺癌患者中,于治疗开始前和耐药发生后采集组织和cfDNA样本。
- 使用全基因组和靶向测序分析遗传改变,并构建体外耐药细胞系进行验证。
主要发现
- 莫博赛替尼耐药时观察到EGFR扩增(n=6,包括2例广泛拷贝数增加)和EGFR二次突变(n=3)。
- 1例患者同时具有EGFR二次突变和高水平EGFR局灶扩增。
- 体外模型证实获得性EGFR依赖性改变介导莫博赛替尼耐药。
- 6例接受序贯埃万妥单抗后EGFR酪氨酸激酶抑制剂治疗的患者中,2例有MET扩增并显示部分缓解。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mobocertinib, an EGFR exon 20 insertion (Ex20ins)-specific tyrosine kinase inhibitor has been used for treatment of advanced/metastatic EGFR Ex20ins-mutant non-small cell lung cancer (NSCLC). However, resistance mechanisms to EGFR Ex20ins-specific inhibitors and the efficacy of subsequent amivantamab treatment is unknown. METHODS: To investigate resistance mechanisms, tissue and cfDNA samples were collected before treatment initiation and upon development of resistance from NSCLC patients with EGFR Ex20ins mutations received mobocertinib, poziotinib, and amivantamab treatments. Genetic alterations were analyzed using whole-genome and targeted sequencing, and in vitro resistant cell lines were generated for validation. RESULTS: EGFR amplification (n = 6, including 2 broad copy number gain) and EGFR secondary mutation (n = 3) were observed at the resistance of mobocertinib. One patient had both EGFR secondary mutation and high EGFR focal amplification. In vitro models harboring EGFR alterations were constructed to validate resistance mechanisms and identify overcoming strategies to resistance. Acquired EGFR-dependent alterations were found to mediate resistance to mobocertinib in patients and in vitro models. Furthermore, two of six patients who received sequential amivantamab followed by an EGFR tyrosine kinase inhibitor had MET amplification and showed partial response. CONCLUSIONS: Our study revealed EGFR-dependent and -independent mechanisms of mobocertinib resistance in patients with advanced EGFR Ex20ins-mutant NSCLC.
引用
- Park S, Park S, Kim TM, et al. Resistance mechanisms of EGFR tyrosine kinase inhibitors, in EGFR exon 20 insertion-mutant lung cancer. Eur J Cancer. 2024. PMID: 38981315. doi:10.1016/j.ejca.2024.114206
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。